Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1926-2015Class II

Lactate. Intended for use on COBAS INTEGRA 800 and 400 plus systems, cobas c111, Roche/Hitachi MODULAR...

Roche Diagnostics GmbH / initiated 2015-05-07 / Terminated

Roche Diagnostics Operations, Inc. began a recall of Lactate. Intended for use on COBAS INTEGRA 800 and 400 plus systems, cobas c111, Roche/Hitachi MODULAR systems, and cobas c systems for the quantitative... on . FDA classified it as Class II and gives the reason as "Possible drug interference when using the Trinder reaction method on multiple Cobas Analyzers. Results of Trinder tests may be falsely decreased when the tests are run with urine samples (Creatinine plus and Uric Acid...". As of , the recall status on record is Terminated.

Recall record

Recall number
Z-1926-2015
Classification
Class II
Status
Terminated
Initiated
Posted
Terminated
Recalling firm
Roche Diagnostics GmbH
Product
Lactate. Intended for use on COBAS INTEGRA 800 and 400 plus systems, cobas c111, Roche/Hitachi MODULAR systems, and cobas c systems for the quantitative determination of lactate concentration in plasm and cerebrospinal fluid.
Product code
CFJ Nad Reduction/Nadh Oxidation, Lactate Dehydrogenase
Reason for recall
Possible drug interference when using the Trinder reaction method on multiple Cobas Analyzers. Results of Trinder tests may be falsely decreased when the tests are run with urine samples (Creatinine plus and Uric Acid applications only) or blood samples collected before sufficient time has lapsed after the administration of the drugs Acetaminophen and N-acetylcysteine.
FDA root cause
Under Investigation by firm
Action
Roche Diagnostics initiated a voluntary recall and the Urgent Medical Device Correction notices were sent via UPS Ground on 05/07/2015 to customers. Customers were notified of the interference and the method sheets and package inserts will be updated with the new interference claims. The firm plans to monitor any non-responding accounts and address those customers with follow-up attempts to distribute recall notices. The firm plans to conduct level B effectiveness checks via fax and phone. Until the new method sheets are available, the Urgent Medical Device Correction serves as the updated labeling. Roche is not requesting return of the affected product. Customers may contact Todd Siesky Corporate Communications Director, Phone: 317.521.3911, Fax: 317.521.4696, E-mail: [email protected]. For technical questions, contact the Customer Support Center at 1-800-428-2336
Quantity in commerce
6255
Distribution
US (nationwide) including PR.
Product codes and lots
Catalog Numbers: 11822837190; 05401666190; 03183700190; 05171881190; 03183700190.

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1926-2015
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1920-2015Class IITerminatedVoluntary: Firm initiated
Z-1921-2015Class IITerminatedVoluntary: Firm initiated
Z-1922-2015Class IITerminatedVoluntary: Firm initiated
Z-1923-2015Class IITerminatedVoluntary: Firm initiated
Z-1924-2015Class IITerminatedVoluntary: Firm initiated
Z-1925-2015Class IITerminatedVoluntary: Firm initiated
Z-1926-2015Class IITerminatedVoluntary: Firm initiated
Z-1927-2015Class IITerminatedVoluntary: Firm initiated
Z-1928-2015Class IITerminatedVoluntary: Firm initiated
Z-1929-2015Class IITerminatedVoluntary: Firm initiated
Z-1930-2015Class IITerminatedVoluntary: Firm initiated
Z-1931-2015Class IITerminatedVoluntary: Firm initiated